Live Breaking News & Updates on Davidw Boyer

Stay updated with breaking news from Davidw boyer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

13,590 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 13,590 shares of the company’s stock, valued at approximately $1,282,000. Other institutional investors have also modified their holdings […] ....

Davidw Boyer , Garya Lyons , Neurocrine Biosciences , Raymond James , Kb Financial Partners , Lisanti Capital Growth , Neurocrine Biosciences Inc , Acadian Asset Management , Bessemer Group Inc , Securities Exchange Commission , Covestor Ltd , Free Report , Asset Management , Wealth Management , Bessemer Group , Get Free Report , Director Gary , Exchange Commission , Visit Holdingschannel , Neurocrine Biosciences Daily , Nasdaq Nbix , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $131.46 Average PT from Analysts

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-one research firms that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 1 year […] ....

United States , Davidw Boyer , Ingrid Delaet , Neurocrine Biosciences , Royal Bank , Hightower Advisors , Neurocrine Biosciences Company Profile , Acadian Asset Management , Neurocrine Biosciences Inc , Financial Services Group Inc , Rice Hall James Associates , Dimensional Fund Advisors , Get Free Report , Hall James , Tower Advisors , Services Group , Asset Management , Fund Advisors , Get Free , Neurocrine Biosciences Daily , Nasdaq Nbix ,

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) have been given an average rating of “Moderate Buy” by the twenty-one analysts that are presently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average […] ....

Davidw Boyer , Neurocrine Biosciences , Ingrid Delaet , Bluepath Capital Management , Royal Bank , Acadian Asset Management , Covestor Ltd , Bessemer Group Inc , Neurocrine Biosciences Company Profile , Neurocrine Biosciences Inc , Kb Financial Partners , Get Free Report , Marketbeat Ratings , Asset Management , Path Capital Management , Get Free , Neurocrine Biosciences Daily , Nasdaq Nbix ,

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $114.00 at Mizuho

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its target price dropped by stock analysts at Mizuho from $116.00 to $114.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Mizuho’s target price points to a potential upside of 6.37% from the stock’s current price. […] ....

Nova Scotia , Kevin Charles Gorman , Piper Sandler , Davidw Boyer , Neurocrine Biosciences , Royal Bank , Jpmorgan Chase Co , Neurocrine Biosciences Inc , Blackrock Inc , Armistice Capital , Norges Bank , Get Free Report , Biosciences Stock Down , Charles Gorman , Neurocrine Biosciences Daily , Nasdaq Nbix , Lower Price Target ,